Limits...
Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4.

Zekri AR, Alam El-Din HM, Bahnassy AA, Zayed NA, Mohamed WS, El-Masry SH, Gouda SK, Esmat G - Comp Hepatol (2010)

Bottom Line: HCC patients had higher levels of liver enzymes but lower log-HCV titer when compared to the other groups.HCC patients had also significantly higher levels of sFas, sTNFR-II and IL-2R and significantly lower levels of IL-8 when compared to the other groups.Exclusion of HCC among patients having PNALT could be predicted with 90 % sensitivity and 70.6 % specificity when sTNFR-II is [greater than or equal to] 389 pg/ml or IL-8 is < 290 pg/ml.

View Article: PubMed Central - HTML - PubMed

ABSTRACT

Background: Liver disease progression from chronic hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC) is associated with an imbalance between T-helper 1 and T-helper 2 cytokines. Evaluation of cytokines as possible candidate biomarkers for prediction of HCC was performed using soluble Fas(sFas), soluble tumor necrosis factor receptor-II (sTNFR-II), interleukin-2 receptor (IL-2R) and interleukin-8 (IL-8).

Results: The following patients were recruited: 79 with HCV infection, 30 with HCC, 32 with chronic liver disease associated with elevated liver enzyme levels (with or without cirrhosis) in addition to 17 with chronic HCV with persistent normal alanine aminotransferase levels (PNALT). Nine normal persons negative either for HCV or for hepatitis B virus were included as a control group. All persons were tested for sFas, sTNFR-II, IL-2R and IL-8 in their serum by quantitative ELISA. HCC patients had higher levels of liver enzymes but lower log-HCV titer when compared to the other groups. HCC patients had also significantly higher levels of sFas, sTNFR-II and IL-2R and significantly lower levels of IL-8 when compared to the other groups. Exclusion of HCC among patients having PNALT could be predicted with 90 % sensitivity and 70.6 % specificity when sTNFR-II is [greater than or equal to] 389 pg/ml or IL-8 is < 290 pg/ml.

Conclusions: Serum TNFR-II, IL-2Ralpha and IL-8, may be used as combined markers in HCV-infected cases for patients at high risk of developing HCC; further studies, however, are mandatory to check these findings before their application at the population level.

No MeSH data available.


Related in: MedlinePlus

Scatter diagram of the distribution of log-HCV titer results among the different study groups. PNALT: Chronic hepatitis C with persistent normal alanine aminotrasferase; CLD: Chronic liver disease; HCC: hepatocellular carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2819041&req=5

Figure 1: Scatter diagram of the distribution of log-HCV titer results among the different study groups. PNALT: Chronic hepatitis C with persistent normal alanine aminotrasferase; CLD: Chronic liver disease; HCC: hepatocellular carcinoma.

Mentions: The clinical characteristics of the studied groups are shown in Table 1. All recruited patients were positive for HCV antibodies, PCR for HCV RNA and all had genotype-4. Mean age of patients with HCC was significantly higher than that of the other groups (p < 0.001). Liver function tests were significantly elevated, whereas log-HCV titer was significantly lower in HCC patients (p < 0.001) when compared to patients with chronic hepatitis C with persistent normal alanine aminotransferase levels (PNALT) and chronic liver disease (CLD) patients. Figure 1 shows the distribution of log-HCV titer in the different study groups, which included 68 men and 29 women. Mann-Whitney test was used for comparing log-HCV, sFas, sTNFR-II, sIL-2R and IL-8 values with gender. Comparing the means of men versus women, the former had only higher and significant (p = 0.04) log-HCV titer (11.16 ± 4.1) and (9.7 ± 1.5), respectively; however, all other markers did not statistically differ.


Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4.

Zekri AR, Alam El-Din HM, Bahnassy AA, Zayed NA, Mohamed WS, El-Masry SH, Gouda SK, Esmat G - Comp Hepatol (2010)

Scatter diagram of the distribution of log-HCV titer results among the different study groups. PNALT: Chronic hepatitis C with persistent normal alanine aminotrasferase; CLD: Chronic liver disease; HCC: hepatocellular carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2819041&req=5

Figure 1: Scatter diagram of the distribution of log-HCV titer results among the different study groups. PNALT: Chronic hepatitis C with persistent normal alanine aminotrasferase; CLD: Chronic liver disease; HCC: hepatocellular carcinoma.
Mentions: The clinical characteristics of the studied groups are shown in Table 1. All recruited patients were positive for HCV antibodies, PCR for HCV RNA and all had genotype-4. Mean age of patients with HCC was significantly higher than that of the other groups (p < 0.001). Liver function tests were significantly elevated, whereas log-HCV titer was significantly lower in HCC patients (p < 0.001) when compared to patients with chronic hepatitis C with persistent normal alanine aminotransferase levels (PNALT) and chronic liver disease (CLD) patients. Figure 1 shows the distribution of log-HCV titer in the different study groups, which included 68 men and 29 women. Mann-Whitney test was used for comparing log-HCV, sFas, sTNFR-II, sIL-2R and IL-8 values with gender. Comparing the means of men versus women, the former had only higher and significant (p = 0.04) log-HCV titer (11.16 ± 4.1) and (9.7 ± 1.5), respectively; however, all other markers did not statistically differ.

Bottom Line: HCC patients had higher levels of liver enzymes but lower log-HCV titer when compared to the other groups.HCC patients had also significantly higher levels of sFas, sTNFR-II and IL-2R and significantly lower levels of IL-8 when compared to the other groups.Exclusion of HCC among patients having PNALT could be predicted with 90 % sensitivity and 70.6 % specificity when sTNFR-II is [greater than or equal to] 389 pg/ml or IL-8 is < 290 pg/ml.

View Article: PubMed Central - HTML - PubMed

ABSTRACT

Background: Liver disease progression from chronic hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC) is associated with an imbalance between T-helper 1 and T-helper 2 cytokines. Evaluation of cytokines as possible candidate biomarkers for prediction of HCC was performed using soluble Fas(sFas), soluble tumor necrosis factor receptor-II (sTNFR-II), interleukin-2 receptor (IL-2R) and interleukin-8 (IL-8).

Results: The following patients were recruited: 79 with HCV infection, 30 with HCC, 32 with chronic liver disease associated with elevated liver enzyme levels (with or without cirrhosis) in addition to 17 with chronic HCV with persistent normal alanine aminotransferase levels (PNALT). Nine normal persons negative either for HCV or for hepatitis B virus were included as a control group. All persons were tested for sFas, sTNFR-II, IL-2R and IL-8 in their serum by quantitative ELISA. HCC patients had higher levels of liver enzymes but lower log-HCV titer when compared to the other groups. HCC patients had also significantly higher levels of sFas, sTNFR-II and IL-2R and significantly lower levels of IL-8 when compared to the other groups. Exclusion of HCC among patients having PNALT could be predicted with 90 % sensitivity and 70.6 % specificity when sTNFR-II is [greater than or equal to] 389 pg/ml or IL-8 is < 290 pg/ml.

Conclusions: Serum TNFR-II, IL-2Ralpha and IL-8, may be used as combined markers in HCV-infected cases for patients at high risk of developing HCC; further studies, however, are mandatory to check these findings before their application at the population level.

No MeSH data available.


Related in: MedlinePlus